Literature DB >> 22785386

Analgesic, antioedematous and antioxidant activity of γ-butyrolactone derivatives in rodents.

Kinga Salat1, Tadeusz Librowski, Andrzej Moniczewski, Krystyna Stanisz-Wallis, Krzysztof Wieckowski, Barbara Malawska.   

Abstract

In this paper, the analgesic, antioedematous, motor-impairing and antioxidant properties of four γ-butyrolactone derivatives (BM113, BM113A, BM138 and BM138A) are described. Pain was induced by thermal (hot-plate test), chemical (writhing test) or mechanical (Randall-Selitto model) stimulation. All in-vivo assays were carried out in mice pretreated intraperitoneally with the test compounds, except for the evaluation of anti-inflammatory and analgesic activities in the carrageenan-induced paw oedema model, in which rats were pretreated orally with these compounds. In the hot-plate assay, BM113A and BM138A dose dependently prolonged the latency of the nociceptive reaction. Their analgesic activity, measured as a median effective dose (ED(50)=4.7 mg/kg), was similar to that of morphine (2.4 mg/kg). In the writhing test, all four compounds, in particular BM113A and BM138A, showed higher potency than the reference drug acetylsalicylic acid (the ED(50) values were 3.7, 2.3 and 46.1 mg/kg, respectively). BM138 caused a dose-dependent diminution of paw oedema (up to 49%) in the carrageenan model and BM138A at 200 mg/kg reduced mechanical hyperalgesia in the Randall-Selitto test (∼30% when compared with the control). None of the γ-butyrolactone derivatives tested at the ED(50) obtained in the hot-plate test influenced the locomotor activity of mice, although in the rotarod test at 24 rpm, BM113A and BM138 at 100 mg/kg showed some motor-impairing properties. In vitro, a concentration-dependent ABTS radical cation-scavenging activity of BM138 and BM138A (up to 80% inhibition of the radical absorbance) was observed. The results of the present study suggest that BM138 and BM138A could be of interest for future investigations as antinociceptive and antioedematous agents with potential free radical-scavenging properties.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785386     DOI: 10.1097/FBP.0b013e3283566042

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  4 in total

1.  Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice.

Authors:  Kinga Sałat; Barbara Filipek
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

2.  Bioactive secondary metabolites from new endophytic fungus Curvularia. sp isolated from Rauwolfia macrophylla.

Authors:  Fatma Kaaniche; Abdelaaty Hamed; Ahmed S Abdel-Razek; Daniel Wibberg; Negera Abdissa; Imene Zendah El Euch; Noureddine Allouche; Lotfi Mellouli; Mohamed Shaaban; Nobert Sewald
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

3.  Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice.

Authors:  Kinga Sałat; Katarzyna Gawlik; Jadwiga Witalis; Dorota Pawlica-Gosiewska; Barbara Filipek; Bogdan Solnica; Krzysztof Więckowski; Barbara Malawska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-14       Impact factor: 3.000

4.  Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.

Authors:  Kinga Sałat; Anna Furgała; Robert Sałat
Journal:  Inflammopharmacology       Date:  2017-10-25       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.